Trade Sales Trump IPOs, Even for Platforms
This article was originally published in Start Up
Executive Summary
Europe's summertime flurry of private biotech sell-offs points to growing pragmatism among management and VCs, and still-poor valuations on the public markets. Firms which haven't already considered the trade sale opportunity should do so--even early-stage, pre-product platform groups.
You may also be interested in...
Specialty Pharma: Tapping Japan
Economic recovery, pharmaceutical consolidation, and a burgeoning private equity sector have encouraged a new cluster of Japan-focused specialty pharmas
Specialty Pharma: Tapping Japan
Economic recovery, pharmaceutical consolidation, and a burgeoning private equity sector have encouraged a new cluster of Japan-focused specialty pharmas
IPO Failures Can Set Up Biotech Successes
Did the 31 biotechs who pulled IPOs since 2003 destroy value? By and large, no-thanks to a growing variety of financing and exit options, most thanks to Pharma's increasing appetite for high-value deals and deeper private equity pockets.